BREAST CANCER: WHAT SHOULD OBSTETRICIAN-GYNECOLOGIST KNOW?

Here we review the epidemiology and screening of breast cancer, a malignant tumor responsible for around 21% of all cancer cases. Risk factors of breast cancer include early menarche, late menopause, overweight/obesity, smoking, alcohol abuse, and genetic presdisposition. Despite the current advances in treatment, in situ breast cancer is rarely diagnosed (1.3%), while 29% of cases are diagnosed at the stage III or IV. Diagnosis of breast cancer is based on medical history, assessment of signs and symptoms, mammography, breast ultrasound examination, and magnetic resonance imaging. Currently, patients with benign breast conditions should be supervised by an obstetrician-gynecologist and receive proper medications. Conservative treatment of benign breast conditions include psychotherapy and use of progesterone, indole-3-carbinol, and Vitex agnus-castus preparations.

рак молочной железы, доброкачественная дисплазия молочной железы, маммография, ультразвуковое исследование молочной железы, скрининг, профилактика, breast cancer, benign breast conditions, screening, prevention, mammography, breast ultrasound examination

1. Состояние онкологической помощи населению России в 2016 году / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена филиал ГБУ «НМИРЦ» Минздрава России, 2017. 236 с.

2. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность / под ред А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена филиал ФГБУ«НМИРЦ» Минздрава России, 2018. 250 с.

3. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017; 317 (23): 2402-2416. doi: 10.1001/ jama.2017.7112.

4. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001; 358 (9291): 1389-1399.

5. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012; 13 (11): 1141-1151.

6. Rojas K, Stuckey P. Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016; 59 (4): 651-672.

7. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Вody Fatness and Cancer - Viewpoint of the IARC Working Group. N Engl J Med. 2016; 375 (8): 794-798. doi: 10.1056/NEJMsr1606602.

8. Gaudet MM, Carter BD, Brinton LA, Falk RT, Gram IT, Luo J, et al. Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies. Int J Epidemiol. 2017; 46 (3): 881-893. doi: 10.1093/ije/dyw288.

9. Вoyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007; 356 (3): 227-236.

10. Гинекология: национальное руководство / под ред. Г.М. Савельева, и др. Москва: ГЭОТАР-Медиа, 2017. 1008 с.

11. Lehman CD, Wellman RD, Buist DS, Kerlikowske K, Tosteson AN, Miglioretti DL, et al. Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. JAMA Intern Med. 2015; 175 (11): 1828-1837. doi: 10.1001/jamainternmed.2015.5231.

12. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast Cancer Screening - Viewpoint of the IARC Working Group. N Engl J Med. 2015; 372 (24): 2353-2358. doi: 10.1056/NEJMsr1504363.

13. Клинические рекомендации РООМ по скринингу рака молочной железы / под ред. Н.А. Захаровой, В.Ф. Семиглазова, Г.М. Манихас. Москва, 2015. 18 с.

14. Breast screening: programme overview - GOV.UK [Electronic resource]. URL: https://www.gov.uk/guidance/breastscreening-programme-overview (accessed 12/07/2018).

15. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015; 314(15): 1599-15614. doi: 10.1001/ jama.2015.12783.

16. Sardanelli F, Aase HS, Álvarez M, Azavedo E, Baarslag HJ, Balleyguier C, et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. Eur Radiol. 2017; 27 (7): 2737-2743. doi: 10.1007/s00330-016-4612-z.

17. Kushi LH, Doyle C, McCullough M, Rock CL, DemarkWahnefried W, Bandera EV, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012. 62 (1): 30-67. doi: 10.3322/caac.20140.

18. Сollaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002; 360 (9328): 187-195.

19. NCCN Clinical Practice Guidelines in Oncology [Electronic resource]. URL: https://www.nccn.org/patients/.(accessed 12/07/2018).

20. Practice Bulletin No. 164 Summary: Diagnosis and Management of Benign Breast Disorders. Obstet Gynecol. 2016; 127 (6):1181-1183.

21. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013; 381 (9880): 1827-1834. 10.1016/S0140-6736(13)60140-3.

22. Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016; 212(4): 660-669. doi: 10.1016/j.amjsurg.2016.06.010.